Structures of NHBA elucidate a broadly conserved epitope identified by a vaccine induced antibody

PLoS One. 2018 Aug 22;13(8):e0201922. doi: 10.1371/journal.pone.0201922. eCollection 2018.

Abstract

Neisserial heparin binding antigen (NHBA) is one of three main recombinant protein antigens in 4CMenB, a vaccine for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B. NHBA is a surface-exposed lipoprotein composed of a predicted disordered N-terminal region, an arginine-rich region that binds heparin, and a C-terminal domain that folds as an anti-parallel β-barrel and that upon release after cleavage by human proteases alters endothelial permeability. NHBA induces bactericidal antibodies in humans, and NHBA-specific antibodies elicited by the 4CMenB vaccine contribute to serum bactericidal activity, the correlate of protection. To better understand the structural bases of the human antibody response to 4CMenB vaccination and to inform antigen design, we used X-ray crystallography to elucidate the structures of two C-terminal fragments of NHBA, either alone or in complex with the Fab derived from the vaccine-elicited human monoclonal antibody 5H2, and the structure of the unbound Fab 5H2. The structures reveal details on the interaction between an N-terminal β-hairpin fragment and the β-barrel, and explain how NHBA is capable of generating cross-reactive antibodies through an extensive conserved conformational epitope that covers the entire C-terminal face of the β-barrel. By providing new structural information on a vaccine antigen and on the human immune response to vaccination, these results deepen our molecular understanding of 4CMenB, and might also aid future vaccine design projects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Bacterial / immunology
  • Antigens, Bacterial / chemistry*
  • Antigens, Bacterial / immunology*
  • Bacterial Outer Membrane Proteins / chemistry*
  • Bacterial Outer Membrane Proteins / immunology*
  • Bacterial Vaccines / immunology
  • Carrier Proteins / chemistry*
  • Carrier Proteins / immunology*
  • Epitopes / chemistry*
  • Epitopes / immunology*
  • Humans
  • Models, Molecular
  • Protein Conformation
  • Structure-Activity Relationship

Substances

  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Bacterial Outer Membrane Proteins
  • Bacterial Vaccines
  • Carrier Proteins
  • Epitopes
  • NHBA protein, Neisseria meningitidis

Grants and funding

This study was sponsored by GlaxoSmithKline Biologicals SA. The funder provided support in the form of salaries for authors DV, RC, EB, PLS, GM, MJB, and EM, and also provided support in the form of research material, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials. During this project, MM held a Novartis/GSK Academy PhD Fellowship registered at the University of Padova, Italy.